Decreased expression of airway epithelial Axl is associated with eosinophilic inflammation in severe asthma.


Journal

Allergology international : official journal of the Japanese Society of Allergology
ISSN: 1440-1592
Titre abrégé: Allergol Int
Pays: England
ID NLM: 9616296

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 03 10 2021
revised: 17 02 2022
accepted: 26 02 2022
pubmed: 24 4 2022
medline: 6 7 2022
entrez: 23 4 2022
Statut: ppublish

Résumé

Airway epithelium-derived cytokines are critical to provoke and perpetuate type 2 inflammation in asthma. Yet it is poorly understood how this epithelial cell-driven inflammatory response is negatively regulated. We previously reported that Axl receptor tyrosine kinase was expressed by basal cells in the airway epithelium and had a role in defining their stem cell identity. However, whether and how Axl regulates airway type 2 inflammation remains unknown. We performed immunofluorescence staining to compare Axl expression in airway epithelium between non-asthmatic subjects, mild-moderate asthma and severe asthma. We confirmed this result by interrogating public databases of global gene expression in endobronchial biopsies. We then quantified eosinophil numbers infiltrating into the trachea of wild-type or Axl-knockout mice that were intranasally treated with house dust mite extracts (HDM). Cell-based assays using siRNA targeting Axl were further performed to identify molecules involved in Axl-mediated regulation of inflammation. Histological assessments and transcriptome analyses revealed decreases in protein and mRNA of Axl in airway basal cells of severe asthmatics. This reduction of Axl expression was correlated with infiltration of eosinophils and mast cells in severe asthmatics. Eosinophil infiltration was more evident in the trachea of Axl-knockout mice in response to repetitive HDM administration. siRNA-mediated knockdown of Axl increased mRNA and protein expression of granulocyte macrophage-colony stimulating factor (GM-CSF) in human bronchial epithelial cells. Axl kinase expressed by basal cells may suppress excessive eosinophilic inflammation via inhibition of GM-CSF in the airway. Axl reduction has clinical implications for the pathogenesis of severe asthma.

Sections du résumé

BACKGROUND BACKGROUND
Airway epithelium-derived cytokines are critical to provoke and perpetuate type 2 inflammation in asthma. Yet it is poorly understood how this epithelial cell-driven inflammatory response is negatively regulated. We previously reported that Axl receptor tyrosine kinase was expressed by basal cells in the airway epithelium and had a role in defining their stem cell identity. However, whether and how Axl regulates airway type 2 inflammation remains unknown.
METHODS METHODS
We performed immunofluorescence staining to compare Axl expression in airway epithelium between non-asthmatic subjects, mild-moderate asthma and severe asthma. We confirmed this result by interrogating public databases of global gene expression in endobronchial biopsies. We then quantified eosinophil numbers infiltrating into the trachea of wild-type or Axl-knockout mice that were intranasally treated with house dust mite extracts (HDM). Cell-based assays using siRNA targeting Axl were further performed to identify molecules involved in Axl-mediated regulation of inflammation.
RESULTS RESULTS
Histological assessments and transcriptome analyses revealed decreases in protein and mRNA of Axl in airway basal cells of severe asthmatics. This reduction of Axl expression was correlated with infiltration of eosinophils and mast cells in severe asthmatics. Eosinophil infiltration was more evident in the trachea of Axl-knockout mice in response to repetitive HDM administration. siRNA-mediated knockdown of Axl increased mRNA and protein expression of granulocyte macrophage-colony stimulating factor (GM-CSF) in human bronchial epithelial cells.
CONCLUSIONS CONCLUSIONS
Axl kinase expressed by basal cells may suppress excessive eosinophilic inflammation via inhibition of GM-CSF in the airway. Axl reduction has clinical implications for the pathogenesis of severe asthma.

Identifiants

pubmed: 35459569
pii: S1323-8930(22)00034-X
doi: 10.1016/j.alit.2022.02.010
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins 0
RNA, Messenger 0
RNA, Small Interfering 0
Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1
Receptor Protein-Tyrosine Kinases EC 2.7.10.1
Axl Receptor Tyrosine Kinase 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-394

Informations de copyright

Copyright © 2022 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.

Auteurs

Koji Itakura (K)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Naoya Fujino (N)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: nfujino@med.tohoku.ac.jp.

Yosuke Kamide (Y)

Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan.

Ikuo Saito (I)

Department of Pathology, Sagamihara National Hospital, Sagamihara, Japan.

Mitsuhiro Yamada (M)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Koji Okutomo (K)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Yoko Tsukita (Y)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Takuya Saito (T)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Tomohiro Ichikawa (T)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Tadahisa Numakura (T)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Yorihiko Kyogoku (Y)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Hiroyuki Aizawa (H)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Yoshinao Ono (Y)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Shuichiro Matsumoto (S)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Tracy Hussell (T)

Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester, UK.

Masami Taniguchi (M)

Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan.

Masakazu Ichinose (M)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Hisatoshi Sugiura (H)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH